Our Senior Partner Campbell Murray enjoyed a thoughtful discussion on syndicate building with industry leaders this week at the @LongwoodLeaders event in Boston.
Final discussion of the day not to be missed - thanks to Miles Gerson, Tony Ho, @Okhalil, Campbell Murray & Lucy Liu for sharing thoughts on structuring the syndicate.
๐๏ธ BLV and its portfolio companies were busy making news in Q3! Here are some highlights from @ReCodeTx and @Cerevance, as well as an addition to our own leadership team.
Keep up to date on all our news: https://t.co/PzJE60CHvt
We are thrilled to announce the newest addition to our team โ please join us in welcoming @Campbel83265527 as our new Senior Partner! With an impressive background in biotech investing and operations, he will undoubtedly help drive our firm to new heights. https://t.co/09R5BGSFc3
Weโre excited to welcome Geney Park to Bioluminescence! Her background in bioengineering and clinical-stage cell therapy, and wide skillset will be invaluable as we continue to support and invest in transformative platform technology companies that aim to improve humanity.
What an insightful discussion! Thanks to everyone who attended yesterdayโs #BIO2024 panel, as well as moderator @gwendolynawu and fellow panelists @AymanAlabdallah, Nate Chang, and @Car0lyn_Ng
How can #biopharma companies reduce time-to-market without compromising quality? Incorporate a patient-first approach into scientific, target-first conversations, advises BLV partner Andy Seid. See what other insights he has shared with Pharma's Almanac: https://t.co/5sOqTaZKkN
What better way to start the year than with celebrations and collaborations? It was a busy #JPM24, and not just for business dealings. We enjoyed connecting with colleagues old and new. Here's to a successful 2024! ๐ฅ
Great news for the New Year: Bioluminescence Ventures announces four distinguished partners whose fusion of science & business acumen will help steer our commitment to transformative #biotech investments
https://t.co/KZSyZLfRBt
Exciting news: Bioluminescence Ventures emerges from stealth with $477M AUM. Led by experienced investor and scientist @KoukiHarasaki, the firm is on a mission to support transformative companies developing therapies for unmet medical needs. Learn more: https://t.co/umo9u11Ab3
What are emerging approaches to drug discovery in #oncology? Join @KoukiHarasaki tomorrow at 1:45 pm, as he leads a #BIO2023 panel including Don Kirkpatrick of @InterlineTx, @dennis_zaller of @rome_tx, Li Peng of @Palleon_Pharma & Christian Dimaano of Kinnate Biopharma.
Bioluminescence founder @KoukiHarasaki will be bringing his insights to #BIO2023 as he leads several expert panels on emerging therapies in #RNA, #oncology and #geneediting. Stay tuned for details, or get a sneak peek here: https://t.co/A8nFTbRvMo
Congratulations to the @EnsomaBio team on the announcement of their $50M Series B Extension financing today. Bioluminescence Ventures is proud to have co-led this round with Kite Pharma/Gilead Sciences. Read more here: https://t.co/JtjaOiXX8A
Congratulations to the @NidoBiosciences team on their launch from stealth yesterday. Bioluminescence Ventures is proud to have led their recent Series B financing. See their news here: https://t.co/GP7hlNQGDV
We're looking forward to hearing about #biotech breakthroughs and industry innovations at #BIO2023! If you'd like to connect or learn more about Bioluminescence Ventures, please reach out to us at [email protected].